Luiza Iuliana Hernandez

Dr. Luiza Iuliana Hernandez


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2016 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
BBBaris A. Borsa
Baris A. Borsa
Bilge Guvenc TunaBilge Guvenc Tuna
Bilge Guvenc Tuna
FHFrank J. Hernandez
Frank J. Hernandez
LHLuiza Iuliana Hernandez
Luiza Iuliana Hernandez
GBGulay Bayramoglu
Gulay Bayramoglu
Veli Cengiz OzalpVeli Cengiz Ozalp
Veli Cengiz Ozalp

13 January 2021 in Cancers
Verified
Journal Article
Open access
PDF file
LHLuiza Iuliana Hernandez
Luiza Iuliana Hernandez
MAMarcos J. Araúzo-Bravo
Marcos J. Araúzo-Bravo
DGDaniela Gerovska
Daniela Gerovska
RSRicardo Rezola Solaun
Ricardo Rezola Solaun
IMIsabel de Barros Machado
Isabel de Barros Machado
FHFrank J. Hernandez
Frank J. Hernandez
Breast cancer is one of the most common pathologies diagnosed in the clinical practice. Despite major advancements in diagnostic approaches, there is no widely accepted biomarker in the clinical practice that can diagnose breast malignancy. Confirmatory diagnosis still relies on the pathological assessment of tissue biopsies by expert pathologists. Thus, there is an unmet need for new types of biomarkers and novel platform technologies that can be easily and robustly integrated into the clinic and that can assist pathologists. Herein, we show that nuclease activity associated to malignant tumors can be used as a novel biomarker in breast cancer, which can be detected via specific degradation of nucleic acid probes. In this study we have identified a set of three chemically modified nucleic acid probes that can diagnose malignancy in biopsy samples with high accuracy (89%), sensitivity (82%) and specificity (94%). This work represents a breakthrough for the potential clinical use of nuclease activity as biomarker, which can be detected via nucleic acids probes, for the clinical diagnosis of malignancy in breast tissue biopsies. This platform technology could be readily implemented into the clinic as adjunct to histopathological diagnostic.

31 October 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
IMIsabel de Barros Machado
Isabel de Barros Machado
GGGarazi Goikoetxea
Garazi Goikoetxea
EAEnara Alday
Enara Alday
TTTania Jiménez Trujillo
Tania Jiménez Trujillo
XAXabier Arias
Xabier Arias
LHLuiza Iuliana Hernandez
Luiza Iuliana Hernandez
The identification of pathogens causing infectious diseases is still based on laborious and time-consuming techniques. Therefore, there is an urgent need for the development of novel methods and devices that can considerably reduce detection times, allowing the health professionals to administer the right treatment at the right time. Lateral flow-based systems provide fast, cheap and easy to use alternatives for diagnosis. Herein, we report on a lateral flow approach for specifically detecting S. aureus bacteria within 6 h.